ELITE STRATEGIC SERVICES

CPT: Senate, House, Department of Commerce, Patent & Trademark Office, Department of Health and Human Services, Centers for Medicare and Medicaid Services, White House Executive Office of the President, Office of Science and Technology Policy S. 708/H.R. 1574 (RESTORE Patent Rights Act) S. 1553/H.R. 3160 (Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act) S. 1546/H.R. 3152 (Patent Eligibility Restoration Act (PERA)) S. 1367/H.R. 2794 (NO FAKES Act) S. 1041 (Affordable Prescriptions for Patients Act) S. 1097 (Interagency Patent Coordination and Improvement Act) Comment on the World Intellectual Property Organization Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge (Docket No. PTO-C-2024-0048) Advancing Americas Interest Act to disadvantageously change U.S. innovator firms access to and treatment before the U.S. International Trade Commission when seeking Section 337 remedies blocking importation of U.S. patent-infringing goods Candidates and nominations for Patent & Trademark Office leadership positions and Patent Public Advisory Committee America First Trade Policy section (3)(e) China intellectual property policies Abuse of section 1498, as requested by Knowledge Ecology International (KEI) of the Department of Health and Human Services (HHS), as drug price controls to expropriate pharma patent rights Abuse of the Inter Partes Review (IPR) process by the Patent Trial & Appeal Boards allowing cases to proceed per the egregious application of the repudiated compelling merits standard for PTAB institution Proposed violation of the Bayh-Dole Act by the government taking a share of the patent licensing royalties of universities patented inventions United Kingdom (UK) Intellectual Property Office (IPO) proposal of a government-run licensing fee-setting scheme for standard-essential patents U.S. Patent and Trademark Office Notice of Proposed Rulemaking (NPRM) to improve the Patent Trial and Appeal Boards (PTAB) practices for instituting inter partes review (IPR) challenges (Docket No. PTO-P-2025-0025) Office of Science and Technology Policy (OSTP) Notice of Request for Information (RFI) on Accelerating the American Scientific Enterprise (Docket No. OSTP-TECH-2025-0100) H.R. 791 (Foreign Anti-Digital Piracy Act) S. 2276/H.R. 3269 (Eliminating Thickets to Improve Competition (ETHIC) Act) H.R. 5811 (Restoring Americas Leadership in Innovation Act (RALIA)) H.R. 1833 (Leadership in Critical and Emerging Technologies (CET) Act) H.R. 861/S. 326 (American Music Fairness Act)

S. 832/H.R. 1492 (Ensuring Pathways to Innovative Cures (EPIC) Act) S. 832/H.R. 1492 (Ensuring Pathways to Innovative Cures (EPIC) Act) Pharmacy benefits management reform Inflation Reduction Act drug price negotiation H.R. 1 (One Big Beautiful Bill Act) provisions related to proposed government drug price controls known as most favored nation being added to the Medicaid or any program H.R. 1 (One Big Beautiful Bill Act) provisions related to Health Savings Account (HSA) reforms Centers for Medicare & Medicaid Services (CMS) Request for Comments on Medicare Drug Price Negotiation Program Draft Guidance, FR Doc. 2025-0860 Reform and eliminate fraud and abuse of the 340B program for pharmaceutical access by providers of indigent care Allowing the Biden-COVID-era Obamacare premium support credits to expire Centers for Medicare & Medicaid Services (CMS) proposed rules, Global Benchmark forEfficient Drug Pricing (GLOBE) for drugs covered under Medicare Part B (Docket No. CMS-2025-1889-0001) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) for drugs covered under Medicare Part D (Docket No. CMS-2025-1888-0001) Elimination of the Center for Medicare and Medicaid Innovation (CMMI) Approval of reauthorization of Floridas Medicaid hospital-directed payment program (DPP) S. 3315 (Health Care Cybersecurity & Resiliency Act) regarding Sen. Bernie Sanderss amendments to codify Most Favored Nation drug price controls

H.R. 384 (One Agency Act) S. 1040 (Drug Competition Enhancement Act) S. 1096 (Preserve Access to Affordable Generics and Biosimilars Act) S. 527 (Prescription Pricing for the People Act) Seeking ways to lower prescription drug prices by promoting competition without expropriating patent rights

S. 587/H.R. 1301 (Death Tax Repeal Act) Reauthorization and making permanent key Tax Cuts and Jobs Act (TCJA) tax policies, i.e., corporate tax rates, progrowth tax incentive provisions H.R. 2230 (Independent Programmers Tax Incentive Act) H.R. 1 (One Big Beautiful Bill Act), provisions related to permanent death tax relief Proposed 1%-5% wealth or success tax on the value of commercialized U.S. patents H.R. 1340/S. 3332 (More Homes on the Market Act) to adjust the home sale capital gains exclusion for inflation H.R. 7687 (No Tax on Takings Act)

Executive Order 14192, Unleashing Prosperity Through Deregulation H. Res. 294 provisions related to proxy voting Government shutdown

Special 301 Report - bolstering U.S. advocacy abroad for respecting intellectual property rights U.S. Trade Representative Request for Comments Regarding Foreign Nations Freeloading on American-Financed Innovation (Docket No. USTR-2025-0011) Employ robust trade policies and pressure tactics to cudgel foreign freeloaders to to stop using drug pricing disparities as a nontariff trade barrier and begin paying their fair share-actual market value-for U.S. medicines U.S. Trade Representative Request for Comments on the Operation of the Agreement between the United States of America, the United Mexican States, and Canada (Docket No. USTR-2025-0004) Urging pursuit in ongoing trade negotiations to ensure Japanese biopharma price controls do not thwart American medical innovation in global markets

H.J. Res. 88, revoking pursuant to the Congressional Review Act California waivers from the Clean Air Act Reform of the definition of the Waters of the United States (WOTUS) under the Clean Water Act

Republican Study Committee FY26 budget proposal

Fannie Mae and Freddie Mac updates permitting mortgage lenders to choose between the current credit score and a new credit score model (Docket No. 2018-27565)

H.J. Res. 140 (Congressional Review Act disapproval of Public Land Order (PLO) 7917) issued by the Biden Administration to withdraw more than 225,000 acres of the Superior National Forest from mineral development for 20 years

Suggesting reforms to adjust cost caps and include certain infrastructure under the Blanket Certificate Program